China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents and licenses for its products GST-HG161, GST-HG141, GST-HG131, and GST-HG121. These patents further strengthen the company’s intellectual property portfolio and global market position.
GST-HG161: Liver Cancer Therapy
GST-HG161 is an oral small-molecule targeted therapy for liver cancer co-developed with China’s leading Contract Research Organization (CRO) Wuxi Apptec. A similar product, the highly selective c-Met inhibitor tepotinib from Merck KGaA, obtained market approval in Japan in March 2020 for use in unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with skipping MET ex14 mutation. GST-HG161 is under patent protection in China, the US, Europe, Canada, Japan, Australia, and other regions. This time, it obtained a patent in the US via the PCT channel.
GST-HG141: Hepatitis B Drug
GST-HG141, a category 1 innovative drug, targets several key factors involved in HBV replication. It is under patent protection in terms of a compound in China, the US, Europe, Japan, South Korea, Canada, Australia, and other regions, and in terms of crystalline form in mainland China, Taiwan, South Korea, Russia, and South Africa. This time, it obtained a patent in Japan.
GST-HG131: First-in-Class HBsAg Inhibitor
GST-HG131, described as a first-in-class hepatitis B surface antigen (HBsAg) inhibitor, previously obtained patents for its compound in Europe, Eurasia, Japan, Australia, mainland China, Hong Kong, and Macau, alongside its crystalline form in mainland China, Taiwan, and South Africa. This time, it obtained patents in Japan and South Korea.
GST-HG121: HBV Surface Antigen Inhibitor
GST-HG121 is a new type of small-molecule HBV surface antigen inhibitor that can block HBV by destabilizing and degrading HBV mRNA. The drug has varying degrees of inhibitory effects on HBV-DNA and HBeAg and offers therapeutic benefits on multiple virological indicators. The inhibitory effect of HBsAg was obvious in in vivo pharmacodynamic experiments in animals, with a good safety profile in preclinical toxicology studies. GST-HG121, with compound invention patent authorizations in China, Japan, South Korea, Europe, and other regions, this time obtained patents in Japan and South Korea.-Fineline Info & Tech
